Most Popular

    Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia

    Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia

    Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macul...

    Planning Underway for Phase 3 Clinical Trial Testing Encapsulated Cell-Based Delivery of CNTF

    Planning Underway for Phase 3 Clinical Trial Testing Encapsulated Cell-Based Delivery of CNTF

    Planning is underway for a Phase 3 clinical trial to test encapsulated cell-based delivery of Ciliary Neurotrophic Factor (CNTF) for the treatment of macular telangiectasia type 2. The decision to run a Phase 3 clinical trial follows the announcemen...